Baek, Minwoo
Choe, Yun-Jeong
Bannwarth, Sylvie
Kim, JiHye
Maitra, Swati
Dorn, Gerald W. II
Taylor, J. Paul
Paquis-Flucklinger, Veronique
Kim, Nam Chul http://orcid.org/0000-0003-1332-3071
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1R56NS112296-01)
Article History
Received: 24 October 2019
Accepted: 3 March 2021
First Online: 26 March 2021
Change Date: 21 April 2021
Change Type: Update
Change Details: The original version of this Article was updated shortly after publication to correct the ORCID ID of Nam Chul Kim.
Change Date: 20 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-23648-1
Competing interests
: G.W.D. is the scientific founder of Mitochondria in Motion, Inc., which has license from WUSTL and is commercializing small-molecule mitofusin agonists for the treatment of neurodegenerative diseases. The remaining authors declare no competing interests.